跳至主要内容
临床试验/NCT00337532
NCT00337532已完成2 期

A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer

Bristol-Myers Squibb2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2005年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
50
试验地点
2
主要终点
Tumor response rate of locally advanced head and neck cancer to a paclitaxel-cisplatin combination regimen in a neoadjuvant setting and administered during maximum 3 cycles.

研究概览

简要总结

The purpose of this clinical research study is to learn if a paclitaxel-cisplatin combination regimen given in the neoadjuvant setting is active in locally advanced head and neck cancer. the safety of this treatment will also be studied.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Locally advanced, Stage II-IV (except M1), hand and neck cancer
  • > = 1 measurable lesion
  • not been previously treated for head and neck cancer

排除标准

  • history of another malignancy
  • organ allografts
  • pre-exiting neuropathy > = CTC grade 2

研究组 & 干预措施

paclitaxel-cisplatin combination regimen

Active Comparator

干预措施: Paclitaxel (Drug)

paclitaxel-cisplatin combination regimen

Active Comparator

干预措施: cisplatin (Drug)

结局指标

主要结局

Tumor response rate of locally advanced head and neck cancer to a paclitaxel-cisplatin combination regimen in a neoadjuvant setting and administered during maximum 3 cycles.

次要结局

  • Toxicity for maximum 3 cycles

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验